Liquid biopsy is a minimally invasive diagnostic approach, which involves examining cancer-related material, such as circulating tumor DNA (ctDNA) from a blood sample. We have shown that pretreatment ctDNA concentration predicts response to therapy and translates to survival in lymphoma patients. We have also shown that changes in the ctDNA concentration during treatment reflect clinical responses to therapy so that the patients who are not responding can be distinguished from the others according to their ctDNA. Our aim is to conduct a clinical trial, which includes lymphoma patients, and uses ctDNA levels and patient reported outcomes (PROs) to guide treatment decisions and evaluate responses. Crucial other activities include comprehensive characterization of lymphomas from the liquid biopsy and tumor tissue, and establishment of a liquid biopsy-based follow-up program. We expect to translate our findings into clinical benefit of lymphoma patients and improved quality of life.

2023

2027